Post Profile






Patients with high risk prostate cancer may benefit 'equally' from two new treatments

(European Society for Medical Oncology) Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.
read more

share

Related Posts


Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

Biothera To Present Research Results At European Society For Medical Oncology World Gastrointestinal Congress

Health : Medical News Today

Biothera has been accepted to present data from its Phase II clinical trial in stage IV KRAS-mutant colorectal cancer at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer June 22-25 in B...

Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the...

Pembrolizumab: promising response rate in pretreated metastatic gastric cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Pembrolizumab has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented today at the ES...

New data confirms superiority of docetaxel based triplet therapy in gastric cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial prese...

Comments


Copyright © 2016 Regator, LLC